Partnering for a Better Biomanufacturing Future
From product supply to co-development and large-scale licensing, Dyadic collaborates with innovators across life sciences, food & nutrition, and industrial biotechnology to make recombinant protein production faster, more affordable, and animal-free.
Flexible Collaboration. Proven Results.
Dyadic’s partnership models are built for flexibility — enabling companies to buy, build, or co-develop solutions using our microbial expression platforms.
We work with partners across the full lifecycle of recombinant protein production — from concept to scale, from licensing to market launch.
Develop
Build custom recombinant strains through Dyadic Applied BioSolutions.
Scale
Access proven production platforms (C1, Dapibus™) for scalable fermentation and manufacturing.
License
License optimized strains or technology for in-house production and commercialization.
Commercialize
Partner to bring new products to market through joint development or shared revenue models.
Multiple Paths, One Goal — Commercial Success
Dyadic partners with companies of all sizes — from start-ups to global manufacturers — using flexible frameworks that accelerate innovation and commercialization.
Partnership Models
What It Offers
Potential Partners
From Biopharma to Bioindustrial — Partnerships Driving Progress
Dyadic’s collaborations span industries and continents, delivering solutions that move science forward:
- Life Sciences: Biologics, vaccines, biologic inputs, and reagents developed in collaboration with biotech, pharmaceutical, and global health organizations.
- Food & Nutrition: Precision fermentation partnerships producing functional and nutritional proteins with ingredient suppliers, food-tech innovators, and nutrition brands.
- Bioindustrial: Enzymes and proteins enabling sustainable, high-performance processes with chemical manufacturers, enzyme formulators, and industrial biotech companies.
“Our partner focused model empowers others to innovate using Dyadic’s proven technology — accelerating access to essential proteins worldwide.”
— Joe Hazelton, President & COO
